Zydus Lifesciences rises on getting USFDA’s approval for Glatiramer Acetate Injection
Zydus Lifesciences is currently trading at Rs. 875.25, up by 3.40 points or 0.39% from its previous closing of Rs. 871.85 on the BSE.
The scrip opened at Rs. 855.85 and has touched a high and low of Rs. 875.25 and Rs. 855.85 respectively. So far 6187 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1323.90 on 09-Aug-2024 and a 52 week low of Rs. 797.05 on 07-Apr-2025.
Last one week high and low of the scrip stood at Rs. 894.20 and Rs. 855.85 respectively. The current market cap of the company is Rs. 87089.55 crore.
The promoters holding in the company stood at 74.99%, while Institutions and Non-Institutions held 18.33% and 6.68% respectively.
Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) for Glatiramer Acetate Injection, 20 mg/mL and 40 mg/mL, single-dose prefilled syringes. Zydus’ generic Glatiramer Acetate Injection is an FDA-approved, AP-rated substitutable generics of Copaxone 20 mg/ml, 40 mg/ml and indicated for the treatment of relapsing forms of Multiple Sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Zydus’ generic Glatiramer Acetate Injection, developed in collaboration with Chemi S.p.A., will be manufactured entirely in Europe. Glatiramer Acetate Injection had annual sales of $719 million in the United States (IQVIA MAT Mar2025). The group now has 426 approvals and has so far filed 492 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.
